Skip to content
Pricing
Sample Reports
Show submenu for Sample Reports
Company Report
Drug Report
Disease Report
Solutions
Show submenu for Solutions
Investors
Portfolio Managers
Research
Publisher Content
Resources
Show submenu for Resources
Case Studies
Demo Videos
Market Intelligence Datasets
Drug Index
FAQs
API Documentation
Company
Show submenu for Company
News & Updates
Leadership
CDD Vault
Contact Us
Login
Pricing
Sample Reports
Show submenu for Sample Reports
Company Report
Drug Report
Disease Report
Solutions
Show submenu for Solutions
Investors
Portfolio Managers
Research
Publisher Content
Resources
Show submenu for Resources
Case Studies
Demo Videos
Market Intelligence Datasets
Drug Index
FAQs
API Documentation
Company
Show submenu for Company
News & Updates
Leadership
CDD Vault
Contact Us
Login
Docosanol
Abreva (docosanol) is a small molecule pharmaceutical. Docosanol was first approved as Abreva on 2000-07-25. It is used to treat blister in the USA.
Trade Name
Abreva
Common Name
Docosanol
Indication
blister
Drug Class